key: cord-0304483-5oyne2aw
authors: Borriello, Francesco; Nanishi, Etsuro; Seo, Hyuk-Soo; O’Meara, Timothy R.; McGrath, Marisa E.; Saito, Yoshine; Haupt, Robert E.; Chen, Jing; Diray-Arce, Joann; Song, Kijun; Xu, Andrew Z; Caradonna, Timothy M.; Feldman, Jared; Hauser, Blake M.; Schmidt, Aaron G.; Baden, Lindsey R.; Ernst, Robert K.; Dillen, Carly; Weston, Stuart M.; Johnson, Robert M.; Hammond, Holly L.; Yu, Jingyou; Chang, Aiquan; Hilgers, Luuk; Platenburg, Peter Paul; Dhe-Paganon, Sirano; Barouch, Dan H.; Ozonoff, Al; Zanoni, Ivan; Frieman, Matthew B.; Dowling, David J.; Levy, Ofer
title: An adjuvanted SARS-CoV-2 RBD nanoparticle elicits neutralizing antibodies and fully protective immunity in aged mice
date: 2021-09-09
journal: bioRxiv
DOI: 10.1101/2021.09.09.459664
sha: 2c8af2684a9447013cb837d89bbabd8c87866a9a
doc_id: 304483
cord_uid: 5oyne2aw

Development of affordable and effective vaccines that can also protect vulnerable populations such as the elderly from COVID-19-related morbidity and mortality is a public health priority. Here we took a systematic and iterative approach by testing several SARS-CoV-2 protein antigens and adjuvants to identify a combination that elicits neutralizing antibodies and protection in young and aged mice. In particular, SARS-CoV-2 receptorbinding domain (RBD) displayed as a protein nanoparticle (RBD-NP) was a highly effective antigen, and when formulated with an oil-in-water emulsion containing Carbohydrate fatty acid MonoSulphate derivative (CMS) induced the highest levels of cross-neutralizing antibodies compared to other oil-in-water emulsions or AS01B. Mechanistically, CMS induced antigen retention in the draining lymph node (dLN) and expression of cytokines, chemokines and type I interferon-stimulated genes at both injection site and dLN. Overall, CMS:RBD-NP is effective across multiple age groups and is an exemplar of a SARS-CoV-2 subunit vaccine tailored to the elderly.

SARS-CoV-2 emerged as a novel betacoronavirus at the end of 2019 and has rapidly spread throughout the world, leading to >150 million cases of Coronavirus Disease 2019 globally including >32 million cases in the US (https://coronavirus.jhu.edu/). This pandemic has generated a global health crisis that will likely be ended only by widespread deployment of effective vaccines across all ages. Historically, the process of vaccine development spans several years. Basic research into prototype betacoronavirus pathogens coupled with advancements in structure-based antigen design, protein engineering and new manufacturing platforms such as mRNA and adenoviral virus vectors have enabled development of effective vaccines at an unprecedented speed Graham, 2020) . Nevertheless, controlling the spread of the virus worldwide and especially in low-and middle-income countries will likely require global deployment of safe, effective, affordable, scalable, and practical vaccines that can also protect highly vulnerable populations including elderly individuals against COVID-19-related morbidity and mortality (Katz et al., 2021; Koff et al., 2021; Lancet Commission on and Therapeutics Task Force, 2021; Mejia et al., 2020) .

Protein subunit vaccines may meet at least some of these criteria and offer further advantages of not requiring ultra-cold storage and have a long track-record of safety.

Indeed, SARS-CoV-2 subunit vaccines have already shown promising results in pre-clinical and clinical studies (Keech et al., 2020; Pollet et al., 2021; Richmond et al., 2021; Tian et al., 2021) .

Most vaccines currently in use or in clinical development target the SARS-CoV-2 Spike glycoprotein due to the key role of its receptor-binding domain (RBD) in binding to the human receptor angiotensin-converting enzyme 2 (ACE2) and mediating cell entry (Lan et al., 2020; Walls et al., 2020b; Yan et al., 2020) . The RBD protein would be an ideal candidate for a subunit vaccine since it is targeted by neutralizing antibodies (Abs) that exert a protective role against SARS-CoV-2 infection and it is readily produced at scale Dalvie et al., 2021a; Dalvie et al., 2021b; Piccoli et al., 2020; Premkumar et al., 2020; Yang et al., 2020) . However, RBD is poorly immunogenic and therefore its use as a candidate antigen poses limitations for vaccine development. To overcome this issue, two non-mutually exclusive approaches can be employed: 1) addition of adjuvant formulations, which are vaccine components that can enhance antigen immunogenicity by activating the innate immune system and/or modulating antigen pharmacokinetics Nanishi et al., 2020; O'Hagan et al., 2020; Pulendran et al., 2021) and 2) structure-based antigen design (Brune and Howarth, 2018; Graham et al., 2019; Irvine and Read, 2020; Kwong et al., 2020; Lopez-Sagaseta et al., 2016; Singh, 2021; Ward and Wilson, 2020) .

Regarding the latter, RBD antigens have been generated as dimers, trimers or displayed onto protein or synthetic nanoparticles with the goal of increasing antigen trafficking to the draining lymph node (dLN) and/or promoting clustering and activation of the B cell receptor (Arunachalam et al., 2021; Cohen et al., 2021; Dai et al., 2020; Dalvie et al., 2021b; Hauser et al., 2020; He et al., 2021; King et al., 2021; Ma et al., 2020; Sahin et al., 2020; Saunders et al., 2021; Tan et al., 2021; Walls et al., 2020a; Walsh et al., 2020) . These approaches have successfully improved RBD immunogenicity and some of them are currently being evaluated in clinical trials (NCT04750343, NCT04742738). Assessing optimal combinations of candidate RBD antigens and adjuvants as well as their evaluation in pre-clinical models that take into account age-dependent vaccine immune responses and COVID-19 susceptibility will be key to down-selecting and prioritizing novel adjuvanted RBD antigenbased vaccines.

Here, we generated a nanoparticle in which multimeric RBD is displayed onto a protein scaffold composed of 60 subunits of the self-assembling bacterial protein lumazine synthase (Zhang et al., 2001) . The RBD nanoparticle (RBD-NP) demonstrated higher immunogenicity compared to pre-fusion stabilized Spike trimer (Wrapp et al., 2020) (hereafter Spike) or monomeric RBD. By comparing multiple adjuvant formulations in combination with RBD-NP we found that a squalene-based oil-in-water (O/W) emulsion containing synthetic Carbohydrate fatty acid MonoSulphate derivative (CMS) (Hilgers et al., 2017) further enhanced anti-RBD serum Ab titers and SARS-CoV-2 cross-neutralizing titers in both young and aged mice. Mechanistically, CMS induced antigen retention in the dLN and expression of pro-inflammatory cytokines at the injection sites and type I interferon (IFN)-dependent IFN stimulated genes (ISGs) in the dLN. Overall, our study demonstrates the utility of a systematic and iterative approach to develop and optimize an adjuvanted RBD-NP effective across multiple age groups and provides further insights into the development of affordable SARS-CoV-2 subunit vaccines tailored to be active in the most vulnerable -i.e., the elderly.

High density display of antigens onto protein NPs increases their immunogenicity and has been employed in several vaccine candidates against viral infections to elicit robust serum antigen-specific Ab titers (Singh, 2021) . In order to assemble SARS-CoV-2 RBD onto a protein NP scaffold we took advantage of the SpyTag/SpyCatcher conjugation system in which proteins fused with SpyTag and SpyCatcher spontaneously form stable isopeptide bonds (Brune et al., 2016) . Briefly, we used the self-assembling lumazine synthase (LuS) from the hyperthermophile "Aquifex aeolicus" as protein NP scaffold (Zhang et al., 2001) , and respectively expressed RBD and LuS with SpyCatcher (RBD-Catch) and SpyTag (LuS-Tag). SDS-PAGE analysis under reducing conditions of RBD-Catch, LuS-Tag, RBD-NP (generated by conjugating RBD-Catch and LuS-Tag) as well as native RBD and Spike proteins confirmed expected molecular weights (Fig. 1A) . Transmission electron microscopy analysis of RBD-NP revealed a ruffled border, suggesting efficient conjugation and display of RBD onto the protein scaffold, and homogeneous size (Fig. 1B) . This impression was further confirmed by dynamic light scattering analysis, showing an average size of ~30 nm ( Fig. 1C) . To confirm proper display of RBD onto NPs, we coated ELISA plates with RBD, Spike, RBD-NP, LuS-Tag, and assessed binding to recombinant human ACE2 (hACE2) and two anti-RBD monoclonal Abs (mAbs: clones H4 and CR3022). RBD-NP binding to hACE2, clones H4 and CR3022 was comparable to RBD and Spike while no binding to LuS-Tag was observed (Fig. 1D, E) . RBD-NP binding profiles remained unaltered under multiple storage conditions, namely five freeze/thaw cycles or storage for 1 week at 4°C or room temperature ( Supplementary Fig. 1) . Interestingly, by assessing binding to mAb clones H4 and CR3022 under lower coating concentrations of RBD, Spike and RBD-NP we observed preferential binding to RBD-NP (Fig. 1F) , suggesting that high density display of RBD onto NP increases Ab avidity. To explore another functional correlate of RBD-NP structure, we performed a competition assay in which Vero cells were incubated with SARS-CoV-2 in the absence or presence of multiple concentrations of RBD, Spike or RBD-NP. RBD-NP significantly reduced SARS-CoV-2 infection as assessed by IC50 and AUC (Supplementary Fig. 2) , further supporting high-density display of RBD onto NP.

To assess whether RBD-NP increases RBD immunogenicity, we immunized BALB/c mice with multiple doses of RBD, Spike or RBD-NP, alone or formulated with the MF59-like O/W emulsion AddaVax using a prime (Day 0) -boost (Day 14) schedule (Fig. 2) . As expected, formulation with AddaVax enhanced anti-RBD Ab titers compared to immunizations with non-formulated antigens. In all experimental conditions, RBD-NP induced highest titers of anti-RBD IgG, IgG1 and IgG2a especially at the lowest tested dose (0.3 μg), thus showing a robust dose-sparing effect. Of note, anti-RBD Abs elicited by immunization with RBD-NP also recognized native RBD on Spike (Supplementary Fig. 3) , which is key for SARS-CoV-2 neutralization. To confirm this point, we performed a surrogate of virus neutralization test (sVNT) that measure the degree of inhibition of RBD binding to hACE2 by immune sera, as well as a neutralization assay with live SARS-CoV-2 virus. In both assays, immunization with RBD-NP formulated with AddaVax induced higher levels of neutralization compared to immunization with Spike ( Fig. 3A, B) , while immunization with monomeric RBD failed to elicit significant levels of neutralization in the sVNT (Fig. 3A) . Of note, immunization with RBD-NP formulated with AddaVax elicited high levels of anti-RBD neutralizing Abs in one additional inbred (C57BL/6) and one outbred (CD-1) mouse strains (Supplementary Fig. 4) .

Overall, these results show that multimeric RBD displayed on a NP significantly enhances its immunogenicity across multiple mouse strains, eliciting high levels of anti-RBD neutralizing Abs with significant dose-sparing effect.

Adjuvants play a key role in enhancing antigen immunogenicity Nanishi et al., 2020; O'Hagan et al., 2020; Pulendran et al., 2021) . Although it is possible to generalize desirable properties for an adjuvant, a proper match between an adjuvant and a specific antigen has to be empirically evaluated. For example, comparisons of O/W-and aluminum hydroxide-based adjuvant formulations with RBD-NP demonstrated that the alpha-tocopherol-containing squalene-based oil-in-water emulsion AS03 is particularly effective at enhancing RBD-NP immunogenicity in non-human primates (Arunachalam et al., 2021) . We therefore evaluated the immunogenicity of our RBD-NP with several O/W emulsions, namely AddaVax, the AS03-like adjuvant AddaS03, and a novel squalene-based O/W emulsion containing Carbohydrate fatty acid MonoSulphate derivative (CMS) (Hilgers et al., 2017) . As a key benchmark, we also included AS01B (a liposome-based adjuvant containing monophosphoryl lipid A and saponin QS-21) as a clinical-grade benchmark adjuvant with potent immunostimulatory activity (Cunningham et al., 2016; Lal et al., 2015) .

As experimental model we chose to immunize both young (3-month-old) and aged (14month-old) mice since we wanted to assess whether an optimized vaccine formulation could overcome impaired vaccine immunogenicity associated with immunosenescence in aged populations (Gustafson et al., 2020) . All adjuvanted RBD-NP vaccine formulations induced robust titers of anti-RBD neutralizing Abs in young mice ( Fig. 4A-E) . Of note, CMSadjuvanted RBD-NP vaccine elicited the highest levels of anti-RBD IgG Abs (Fig. 4A ) by enhancing both anti-RBD IgG and IgG2a titers (Fig. 4B, C) , resulting in potent inhibition of RBD binding to hACE2 (Fig. 4D) and SARS-CoV-2 neutralization (Fig. 4E) . Immunization of aged mice resulted in overall lower anti-RBD Ab titers compared to young mice ( Supplementary Fig. 5) . Nevertheless, CMS again induced the highest anti-RBD antibody titers ( Fig. 4F-H) , inhibition of RBD binding to hACE2 (Fig. 4I) and SARS-CoV-2 neutralization ( Fig. 4J ) in aged mice.

Neutralizing Ab titers are an important correlate of protection against SARS-CoV-2 infection (Corbett et al., 2021; McMahan et al., 2021) . As we observed high titers of neutralizing Abs in our immunization model, we decided to assess protection from SARS-CoV-2 infection by challenging immunized aged mice with 10 3 PFU of the mouse adapted strain SARS-CoV-2 MA10 (Leist et al., 2020) and monitoring them up to four days post-infection (Fig. 5) . Mice immunized with RBD-NP formulated CMS were fully protected from weight loss (Fig. 5A) , and demonstrated low SARS-CoV-2 titers and Il6, Ifit2 and Rsad2 gene expression in the lungs (Fig. 5B, C) .

Since the beginning of the pandemic several SARS-CoV-2 variants such as B.1.17 and B.1.351 have emerged, the latter showing reduced neutralization by serum samples of convalescent or vaccinated subjects (Garcia-Beltran et al., 2021; Kuzmina et al., 2021; Shen et al., 2021) . Therefore, we assessed neutralization of SARS-CoV-2 wild type (WT), B.1.17 and B.1.351 pseudoviruses by serum samples collected from young and aged mice immunized with RBD-NP formulated with AddaVax, AddaS03, CMS or AS01B (Fig. 6) . As expected, we observed lower neutralizing titers against B.1.351 compared to WT. However, mice immunized with RBD-NP formulated with CMS showed the highest geometric mean titers against all SARS-CoV-2 variants, expecially in aged mice.

O/W emulsions are highly effective adjuvants and act through multiple mechanisms, including: 1) induction of a pro-inflammatory milieu at the injection site (Mosca et al., 2008) and/or 2) antigen targeting to and retention in the dLN (Cantisani et al., 2015) . We therefore assessed whether the enhanced adjuvanticity of CMS could be explained by any of these 1 0 two mechanisms. To this end, we injected mice with R-Phycoerythrin (R-PE) as a model protein antigen with intrinsic fluorescence, alone or formulated with CMS or AddaVax that we used as benchmark adjuvant. Twenty four hours post-injection, both AddaVax and CMS promoted significant and comparable antigen retention in the dLN (Supplementary Fig. 6) .

Interestingly, both adjuvants induced high gene expression of pro-inflammatory cytokines (Csf2, Il6, Cxcl1) and ISGs (Cxcl9, Ifit2, Rsad2) at the injection site, with AddaVax further enhancing the expression of the latter (Fig. 7A) . However, only CMS enhanced type I IFNdependent ISG expression in the dLN (Fig. 7B ).

Despite rapid development and deployment of effective SARS-CoV-2 vaccines based on mRNA or viral vector technologies Graham, 2020) , there remains an urgent global need for affordable, scalable, and practical coronavirus vaccines (Katz et al., 2021; Koff et al., 2021; Lancet Commission on and Therapeutics Task Force, 2021; Mejia et al., 2020) . In this context, adjuvanted protein subunit vaccines are likely to play an important role for increasing worldwide vaccine coverage, based in part on their generally robust history of safety and efficacy in special populations such as the infant and the elderly.

Adjuvanted subunit vaccines consisting of Spike or RBD proteins, expressed in soluble or nanoparticle forms, are currently in different stages of pre-clinical and clinical development (Arunachalam et al., 2021; Cohen et al., 2021; Dai et al., 2020; Dalvie et al., 2021b; Hauser et al., 2020; He et al., 2021; Keech et al., 2020; King et al., 2021; Ma et al., 2020; Pollet et al., 2021; Richmond et al., 2021; Saunders et al., 2021; Tan et al., 2021; Tian et al., 2021; Walls et al., 2020a) . On-going efforts are required to define optimal combinations of antigens and adjuvants to enhance immunogenicity across the lifespan. Here, we assessed the immunogenicity of RBD-NP formulated with four different adjuvants, namely the MF59-like

AddaVax, AS03-like AddaS03, AS01B, and CMS. Consistent with prior studies, we found that the first three elicited high levels of anti-RBD neutralized Abs (Arunachalam et al., 2021; King et al., 2021; Walls et al., 2020a) . However, CMS was the most effective at enhancing RBD-NP immunogenicity in both young and aged mice and protected the latter from live SARS-CoV-2 challenge. To provide a mechanistic basis for this phenomenon, we found that CMS promotes antigen retention in the dLN and induced a gene expression profiles at both the injection site and the dLN that are distinct from the ones elicited by AddaVax, including induction of type I IFN-dependent ISGs in the dLN that may promote immunogenicity (De Giovanni et al., 2020) . Overall, our study provides novel mechanistic and translational information on O/W adjuvants and might inform the development of adjuvanted RBD-NP vaccines effective across multiple age groups.

In this study, we compared the immunogenicity of monomeric RBD, Spike and RBD-NP using the same adjuvant formulation, namely AddaVax. As expected, monomeric RBD was poorly immunogenic. RBD-NP was more immunogenic than Spike across all tested dosed.

Our results are supported by the concept that antigen display onto NP scaffold enhances immunogenicity and activate B cells to eventually produce antigen-specific Abs (Brune and Howarth, 2018; Graham et al., 2019; Irvine and Read, 2020; Kwong et al., 2020; Lopez-Sagaseta et al., 2016; Singh, 2021; Ward and Wilson, 2020) . However, a recent study has reported that immunizations of non-human primates with RBD-NP or Spike Hexapro formulated with AS03 elicited comparable SARS-CoV-2 neutralizing titers (Arunachalam et al., 2021) . Whether the differences between these findings and our study are due to use of different reagents (distinct RBD-NP designs, Spike vs Spike Hexapro, AddaVax vs AS03), doses and/or animal models (mice vs non-human primates) has not yet been determined.

Nevertheless, both studies as well as additional recent publications support the use of RBD- To further optimize RBD-NP immunogenicity we compared four adjuvant formulations, namely AddaVax, AddaS03, AS01B and CMS. The first three (or similar adjuvant formulations) increase RBD-NP immunogenicity (Arunachalam et al., 2021; King et al., 2021; Walls et al., 2020a) , with an AS03-adjuvanted RBD-NP being currently evaluated in a clinical trial (NCT04750343). CMS is a potent adjuvant with a low reactogenicity profile (Hilgers et al., 2017) but until now had never been tested with an RBD-NP. The CMS adjuvant technology is a third generation of the so-called carbohydrate fatty acid sulphate estersbased adjuvants such as CoVaccine HT (Blom and Hilgers, 2004) . Compared to CoVaccine HT, CMS has an improved safety profile but similar abilities to induce high antibody titers.

Strikingly, CMS induced the highest levels of anti-RBD IgG Abs in young and aged mice by enhancing both anti-RBD IgG1 and IgG2a. This translated into high SARS-CoV-2 neutralizing titers that protected aged mice from SARS-CoV-2 challenge. Serum samples of mice immunized with RBD-NP formulated with CMS also demonstrated the highest neutralization titers against B.1.17 and B.1.351 pseudoviruses which represent SARS-CoV-2 variants of concern. Therefore, CMS is a promising adjuvant formulation for an RBD-NPbased SARS-CoV-2 vaccine effective across multiple age groups.

To define a mechanistic basis for CMS adjuvanticity, we hypothesized that CMS could induce significant local cytokine and chemokine production at the injection site and/or antigen retention in the dLN. We focused on these mechanisms as they have been described previously for O/W emulsions (Cantisani et al., 2015; Mosca et al., 2008) . By comparing CMS and AddaVax adjuvants, we found that both induced high antigen retention in the dLN and expression of pro-inflammatory genes at the injection site. Cytokine and chemokine production at the injection site can promote innate immune cell recruitment, activation and subsequent antigen presentation (Mosca et al., 2008) . However, only CMS enhanced type I IFN-dependent ISG expression in the dLN which can promote differentiation of CD4 + T follicular helper cells and therefore antigen-specific antibody response (De Giovanni et al., 2020) . Further work will be required to define the precise mechanism of action of CMS, as well as how antigen localization and germinal center dynamics in the dLN are modulated by AddaVax and CMS.

The emergence of SARS-CoV-2 variants that can escape neutralizing Abs elicited by infection or vaccination has raised concerns regarding possible reduction in vaccine efficacy (Garcia-Beltran et al., 2021; Kuzmina et al., 2021; Shen et al., 2021) . While our results show significant neutralization of B.1.17 and B.1.351 pseudoviruses by serum samples of mice immunized with RBD-NP and CMS, it is likely that novel vaccines specifically targeting SARS-CoV-2 variants of concern may need to be rapidly developed . In addition, the risk posed by emerging zoonotic coronaviruses calls for the development of pan-coronavirus vaccines that can protect against circulating variants as well as strains currently circulating only in non-human animals but that can generate future human outbreaks and pandemics. The SpyTag/SpyCatcher conjugation platform employed in our study has recently been used to generate mosaic NP displaying RBD proteins derived from 1 4 up to 8 strains . Whether different adjuvant formulations (e.g. AddaVax, CMS) can modulate the breadth of the Ab response elicited by mosaic RBD-NP is an important area for future research.

Overall, we have described the process of selection and optimization of an adjuvanted RBD-NP vaccine formulation capable of inducing cross-neutralizing Abs and protective immunity across multiple age groups, even at very low doses, and provided a mechanistic basis for its enhanced immunogenicity. Our work may inform further pre-clinical and clinical development of precision adjuvanted RBD-NP-based SARS-CoV-2 and pan-coronavirus vaccines tailored for robust immunogencity and protection in the vulnerable elderly. Both contructs contain a signal peptide (MKHLWFFLLLVAAPRWVLS) at N-terminus and HRV3C protease site, followed by a TwinStrepTag at C-terminus. These mammalian expression vectors were used to transfect Expi293F suspension cells (Thermo Fisher) using polyethylenimine (Polysciences). Cells were allowed to grow in 37°C, 8% CO 2 for additional 5 days before harvesting for purification. Protein was purified in a PBS buffer (pH 7.4) from filtered supernatants by using either StrepTactin resin (IBA) or Cobalt-TALON resin (Takara). Affinity tags were cleaved off from eluted protein samples by HRV 3C protease, and tag removed proteins were further purified by size-exclusion chromatography using a Superose 6 10/300 column (Cytiva) for full length Spike and a Superdex 200 10/300

Increase 10/300 GL column (Cytiva) for RBD, RBD-Catch, and LuS-Tag in a PBS buffer (pH 7.4).

To saturate Lus-Tag surface with RBD, a 1:1.2 molar ratio of LuS-Tag and RBD-Catch components were mixed at 40 µM of LuS-Tag in a PBS buffer (pH 7.4) and incubated at room temperature for approximately 1 hour. Reaction mixture was applied to a Superdex200 Increase 10/300 GL column (Cytiva) in a PBS buffer (pH 7.4) to purify RBD-nanoparticles from unconjugated RBD-Catch. The conjugated RBDnanoparticle product was confirmed by SDS-PAGE and analyzed by negative-stain EM.

(Invitrogen) were heated to 95ºC for 5 min and 10 µl (2.5 µg) were loaded to a NuPAGE Mouse serum antibody ELISA. RBD-and Spike-specific Ab titers were quantified in serum samples by ELISA by modifitation of a previously described protocol (Borriello et al., 2017 calculated as the dilution that emitted an optical density exceeding a 3× background. An arbitrary value of 25 was assigned to samples with OD values below the limit of detection for which it was not possible to interpolate the titer.

We performed sVNT to measure the degree of hACE2/RBD inhibition by immune sera, with modification of a previously published protocol (Tan et al., 2020) . plate. The sample/virus mixture was then incubated at 37°C (5.0% CO 2 ) for 1 hour before transferring 100 µl to 96-well titer plates with 5e3 VeroE6 cells. Titer plates were incubated at 37°C (5.0% CO 2 ) for 72 hours, followed by cytopathic effect (CPE) determination for each well in the plate. The first sample dilution to show CPE was reported as the minimum sample dilution required to neutralize >99% of the concentration of SARS-CoV-2 tested (NT99).

The SARS-CoV-2 pseudoviruses expressing a luciferase reporter gene were generated in an approach similar to as described previously Yu et al., 2020) . 

Adjuvanting a subunit COVID-19 vaccine to induce protective immunity

Sucrose fatty acid sulphate esters as novel vaccine adjuvants: effect of the chemical composition

Identification and Characterization of Stimulator of Interferon Genes As a Robust Adjuvant Target for Early Life Immunization

New Routes and Opportunities for Modular Construction of Particulate Vaccines: Stick, Click, and Glue

Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization

Vaccine adjuvant MF59 promotes retention of unprocessed antigen in lymph node macrophage compartments and follicular dendritic cells

Genetic modification to design a stable yeastexpressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate

Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice

Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates

Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older

A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS

methanol-free manufacturing of the SARS-CoV-2 receptor binding domain in engineered Komagataella phaffii

Engineered SARS-CoV-2 receptor binding domain improves immunogenicity in mice and elicits protective immunity in hamsters

Spatiotemporal regulation of type I interferon expression determines the antiviral polarization of CD4(+) T cells

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

Novel approaches for vaccine development

Rapid COVID-19 vaccine development

Structure-Based Vaccine Antigen Design

Influence of immune aging on vaccine responses

Engineered receptor binding domain immunogens elicit pan-coronavirus neutralizing antibodies

Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates

Carbohydrate fatty acid monosulphate esters are safe and effective adjuvants for humoral responses

Controlling timing and location in vaccines

Shaping humoral immunity to vaccines through antigendisplaying nanoparticles

From Vaccine Nationalism to Vaccine Equity -Finding a Path Forward

Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques

Development and deployment of COVID-19 vaccines for those most vulnerable

SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera

Antibody-guided structure-based vaccines

Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Urgent needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics

Induces Acute Lung Injury and Mortality in Standard Laboratory Mice

Self-assembling protein nanoparticles in the design of vaccines

Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses

Correlates of protection against SARS-CoV-2 in rhesus macaques

Global COVID-19 Efforts as the Platform to Achieving the Sustainable Development Goals

Molecular and cellular signatures of human vaccine adjuvants

Toward precision adjuvants: optimizing science and safety

The continued advance of vaccine adjuvants -'we can work it out

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology

SARSCoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice

The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients

Emerging concepts in the science of vaccine adjuvants

Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, doubleblind, placebo-controlled trial

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

SARS-CoV-2 vaccination induces neutralizing antibodies against pandemic and pre-emergent SARS

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351

Eliciting B cell immunity against infectious diseases using nanovaccines

A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction

A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice

Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2

Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Innovations in structure-based antigen design and immune monitoring for next generation vaccines

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity

Deletion of the SARS-CoV-2 Spike Cytoplasmic Tail Increases Infectivity in Pseudovirus Neutralization Assays

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

X-ray structure analysis and crystallographic refinement of lumazine synthase from the hyperthermophile Aquifex aeolicus at 1.6 A resolution: determinants of thermostability revealed from structural comparisons

We thank the members of the BCH Precision Vaccine Program for helpful discussions. We thank Drs. Kevin Churchwell, Gary Fleisher, David Williams, and Mr. August Cervini for their support of the Precision Vaccines Program. We thank Dr. Barney S. Graham (NIH Vaccine Research Center) for generously providing the plasmid for pre-fusion stabilized SARS-CoV-